Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is obse...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Invest
Prif Awduron: Ruella, Marco, Barrett, David M., Kenderian, Saad S., Shestova, Olga, Hofmann, Ted J., Perazzelli, Jessica, Klichinsky, Michael, Aikawa, Vania, Nazimuddin, Farzana, Kozlowski, Miroslaw, Scholler, John, Lacey, Simon F., Melenhorst, Jan J., Morrissette, Jennifer J.D., Christian, David A., Hunter, Christopher A., Kalos, Michael, Porter, David L., June, Carl H., Grupp, Stephan A., Gill, Saar
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2016
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5096828/
https://ncbi.nlm.nih.gov/pubmed/27571406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87366
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg